人类神经元中的陶耗尽减轻了Aβ驱动的毒性
Bryan Ng1,2, Jane Vowles3, Féodora Bertherat1,2
1Department of Physiology, Anatomy and Genetics, University of Oxford, South Parks Road, Oxford, OX1 3QU, UK.
Molecular psychiatry
|February 16, 2024
概括
这项研究表明,减少人类神经元中的陶蛋白可以保护它们免受阿尔茨海默氏症 (AD) 病理,包括粉样β毒性. 这些发现支持阿尔茨海默病治疗的tau降低策略.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 干细胞生物学 干细胞生物学
背景情况:
- 阿尔茨海默病 (AD) 涉及粉样β (Aβ) 斑块和团.
- 已知Aβ毒性在小鼠模型中是tau依赖的.
- 人类细胞模型缺乏慢性tau降低.
研究的目的:
- 创建和利用人类诱导多能干细胞 (iPSC) 模型,以慢性tau耗尽.
- 调查陶氏在人类细胞中Aβ诱导的神经元功能障碍和神经退行症中的作用.
主要方法:
- 使用CRISPR-Cas9.9生成具有tau枯竭的同源人类iPSC面板.
- 差异化的iPSCs变成皮质神经元,并与星球细胞共同培养.
- 评估了神经元活动,突触密度,神经元外生长,线粒体运输和神经退行.
主要成果:
- 耗减小了神经元活动,但没有影响突触密度.
- 陶耗尽保护神经元免受Aβ诱导的过度活动和线粒体运输缺陷.
- 耗减轻了Aβ诱导的神经退行.
结论:
- 陶对于人类神经元中的Aβ驱动的神经毒性至关重要.
- 慢性降低陶氏的策略显示出对AD病原发生的保护作用.
- 开发的人类iPSC模型为进一步的AD研究提供了一个平台.
更多相关视频
04:41Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices
Published on: July 14, 2010
23.2K
10:19Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
Published on: August 14, 2016
9.3K
相关概念视频
Long-term Depression
2.5K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
2.5K
Alzheimer's Disease: Treatment
189
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
189
Alzheimer's Disease: Overview
484
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
484
